Editas Medicine, Inc.

As of June 30, 2026, Editas Medicine, Inc. carries a market capitalization of 495.90M, placing it among publicly traded companies globally. Its enterprise value stands at 299.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Editas Medicine, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Editas Medicine, Inc. has 153.53M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 6.95, and the price-to-book ratio stands at 4.71.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 299.77M versus a market cap of 495.90M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Editas Medicine, Inc. maintains a current ratio of 3.19, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.73, indicating elevated leverage, while an interest coverage ratio of -18.05 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Editas Medicine, Inc. posted a negative return on equity (ROE) of -118.82, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.02, reflecting losses generated across the asset base. The company generates approximately 370,848.13 in revenue per employee across its workforce of 126.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Editas Medicine, Inc.'s stock has declined approximately 30.56% over the past 52 weeks. The 50-day moving average sits at 2.79, while the 200-day moving average is 2.65.

Over the twelve months ended June 30, 2026, Editas Medicine, Inc. generated 47.01M in revenue and converted that into -73.95M in net income, yielding earnings per share of -0.73. EBITDA reached -73.43M, while operating income came in at -83.46M.

As of June 30, 2026, Editas Medicine, Inc. holds 211.65M in cash and equivalents against 15.51M in total debt, resulting in a net debt position of -181.81M. Total book value stands at 105.28M, with working capital of 149.63M providing operational flexibility.

Editas Medicine, Inc. produced -119.86M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -691,000.00 in capital expenditures, free cash flow totaled -120.55M - equivalent to -1.19 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -177.56 and net profit margin of -157.32 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -36.91: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -30.66, meaning Editas Medicine, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Editas Medicine, Inc. has an Altman Z-Score of -7.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.